Establishment of Hercynian operation center
Nanjing Pharmaceutical Co., Ltd. has come, the first listed company in the domestic pharmaceutical distribution industry, is ready to invest in Xiamen's Huli District to set up a Nanjing Pharmaceutical Hercynian operation center, to continue to develop its Fujian market map.
Industry insiders analyze, Nanjing Pharmaceuticals stationed in Xiamen, or will trigger a new round of mergers and acquisitions in the Fujian pharmaceutical market.
Nanjing Pharmaceutical's Xiamen base is made up of converted factory buildings.
Shareholders' lawsuit case in court, involving subsidiary equity transfer suspense
On October 13, 2014, a class action lawsuit by shareholders against Nanjing Pharmaceuticals was opened in the Nanjing Intermediate Court.
In March 2014, the Jiangsu Provincial Bureau of Securities Regulatory Commission penalized Nanjing Pharmaceuticals for failing to disclose information in a timely manner, which led to the filing of a lawsuit against Nanjing Pharmaceuticals by the shareholders, who demanded that Nanjing Pharmaceuticals pay compensation for the losses brought by failing to disclose information in a timely manner. losses.
Nanjing Pharmaceuticals hid the transaction by selling the subsidiary and then buying it at a premium, deviating from normal business logic.
The three pieces of information are: the matter of giving up the priority right to increase the capital of Nanjing Pharmaceutical Yandu Co, Ltd, the matter of giving up the priority right to increase the capital of Nanjing Pharmaceutical International Health Industry Co, Ltd, and the matter of entrusting NPharm International with the acquisition of 86.825% of the equity of Yancheng Hengjian Pharmaceutical Co, Ltd.
In the process of the two sides' court defense, the deadline of the shareholders' damaged day became the focus of argument. Wang Zhibin said, the above three major transactions occurred in 2011, Nanjing Pharmaceuticals that the latter two transactions company on March 7, 2012 supplemental announcement, the first transaction announcement time should be March 20, 2014. This means that as long as the shareholders who held NJM before March 20, 2014, they have the right to make a claim.
On October 17, 2011, the board of directors of Nanjing Pharmaceutical passed a resolution to give up the right of priority capital increase of its wholly-owned subsidiary, Yandu Pharmaceutical. on October 18, Nanjing Pharmaceutical signed an agreement with Shaanxi Hehe Pharmaceutical System Investment Management Co. Ltd. in which Shaanxi Hehe increased its capital to Yandu Pharmaceutical by 116 million yuan, 65.9 million yuan of which was the registered capital and 50.1 million yuan of which was the capital reserve fund. After the capital increase, Shaanxi Hehe holds 86.825% of Yandu Pharmaceutical's equity and Nanjing Pharmaceutical holds 13.175%. At the same time, the name of Yandu Medicine was changed to Yancheng Hengjian, and the legal representative was changed to Sun Weizeng, and the above changes were registered on October 21, 2011 for industrial and commercial changes.